Cargando…
Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma
BACKGROUND: Recurrent hepatitis C virus (HCV) infection of transplanted liver allografts is universal in patients with detectable HCV viremia at the time of transplantation. Direct-acting antiviral (DAA) therapy has been adopted as the standard of care for recurrent HCV infection in the post-transpl...
Autores principales: | Ismail, Mohamed Saleh, Hassan, Manal, Khaderi, Saira Aijaz, Yousry, Wael Ahmed, Kamal El-Din, Maha Mohsen, Bahaa El-Din, Mohamed Mohamed, El Sayed, Osama Aboelfotoh, Kaseb, Ahmed Omar, Goss, John Alan, Kanwal, Fasiha, Jalal, Prasun Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522560/ https://www.ncbi.nlm.nih.gov/pubmed/33033569 http://dx.doi.org/10.4254/wjh.v12.i9.628 |
Ejemplares similares
-
Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma
por: Ismail, Mohamed Saleh, et al.
Publicado: (2021) -
Radiological‐histopathological discordance in patients transplanted for HCC and its impact on post‐transplant outcomes
por: Mohamed, Islam B., et al.
Publicado: (2023) -
Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves
por: El Kassas, Mohamed, et al.
Publicado: (2019) -
Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study
por: El-Serag, Hashem B., et al.
Publicado: (2023) -
Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma
por: Shaikh, Anjiya, et al.
Publicado: (2022)